Raymond James Initiates Coverage of Quince Therapeutics at Outperform
Fintel reports that on October 9, 2026, Raymond James initiated coverage of Quince Therapeutics (NASDAQGS:QNCX) with a Outperform recommendation. On the day of this rating action, October 9, 2026, the stock closed at $31.73. This followed a pre-action close of $29.36 on October 8, 2026.
The stock has experienced recent price fluctuations, with a one-week price change of +8.66% relative to a baseline close of $29.20 on October 2, 2026. Over a one-month period, the price change was +4.67% from a baseline close of $30.32 on September 9, 2026. Other analysts have also recently adjusted their outlooks on Quince Therapeutics. On September 24, 2026, Rodman & Renshaw initiated coverage with a Buy rating. Prior to that, on September 22, 2026, Citizens upgraded the stock from Market Perform to Market Outperform.
As of October 2, 2026, the current consensus target mean for the stock was $76.94, while the current consensus target median was $71.40, representing an implied change of +142.47%. This consensus target mean represents a revision of -5.12% from the prior consensus target mean of $81.09 recorded on September 15, 2026. In terms of aggregate analyst recommendations, the current recommendation period as of September 1, 2026, showed a total of 13 recommendations, consisting of 4 strong buy, 5 buy, and 4 hold recommendations, with 69.2% positive and 30.8% hold ratings.
Quince Therapeutics reported its latest earnings on August 14, 2026. The company reported an actual EPS of -12.31, compared to an estimated EPS of -18.2376. Both actual revenue and estimated revenue for the period were $0.00. In regulatory filings, the company filed a DEF 14A Definitive Proxy Statement on August 25, 2026. Subsequently, in a Form 8-K filed on September 4, 2026, the company disclosed that if its compliance plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from the date of the Notice, or until February 27, 2027, to evidence compliance. The filing noted that to regain compliance, the company must have stockholders’ equity of at least $10,000,000, and that the company was currently evaluating various alternative courses of action to regain compliance.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| October 9, 2026 | Raymond James | Outperform | initiated coverage | |
| September 24, 2026 | Rodman & Renshaw | Buy | initiated coverage | |
| September 22, 2026 | Citizens | Market Perform | Market Outperform | upgrade |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.